Attenuation in the progression of cognitive deterioration in alzheimer's disease with rivastigmine: A dose-dependent effect

Martin Farlow, John Messina, Ravi Anand, Richard Hartman, Jeffrey Veach

Research output: Contribution to journalArticle

Abstract

Objectives: Possible disease-modifying effects ofrivastigmine have been suggested by analyses using a variation of the randomized start design; however, the results were someichat confounded by differing attrition rales. We report on an alternative method investigating whether increasing doses reduce the rates of cognitive decline in patients who continue treatment. Methods: The effect of dose on the rate of cognitive decline seen on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASCog) u'as explored for patients in a long-term (130-iceek) extension of a 26-iceek placebo-controlled trial using two methods: a weighted least squares regression analysis using each individual's slope, and a weighted analysis of variance (ANOVA) comparing the slopes of patients categorized by dose (<6 mg/d or >6 mg/d). Results: The results from 408 patients included in the weighted least squares analysis estimated the rate of decline to attenuate by approximately 1 point/yfor every 3 mg/d increase (P<.0001). The average annual rate of decline for patients whose mean dose was >6 mg/d w-as 4.5 points (95% Cl, 5.1-3.9), while for patients with a mean dose of>6 mg/d a decline of 8.2 points (95% Cl, 9.1-7.3) was seen. Conclusion: These data further support earlier results suggesting that rivastigmine reduces the rate of progression of cognitive deterioration in Alzheimer's disease.

Original languageEnglish
Pages (from-to)21-22
Number of pages2
JournalCNS Spectrums
Volume5
Issue number6
StatePublished - 2000

Fingerprint

Rivastigmine
Alzheimer Disease
Least-Squares Analysis
Respiratory Sounds
Analysis of Variance
Placebos
Regression Analysis

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Attenuation in the progression of cognitive deterioration in alzheimer's disease with rivastigmine : A dose-dependent effect. / Farlow, Martin; Messina, John; Anand, Ravi; Hartman, Richard; Veach, Jeffrey.

In: CNS Spectrums, Vol. 5, No. 6, 2000, p. 21-22.

Research output: Contribution to journalArticle

Farlow, Martin ; Messina, John ; Anand, Ravi ; Hartman, Richard ; Veach, Jeffrey. / Attenuation in the progression of cognitive deterioration in alzheimer's disease with rivastigmine : A dose-dependent effect. In: CNS Spectrums. 2000 ; Vol. 5, No. 6. pp. 21-22.
@article{7e483304f42b491cb7fcf506952f0e81,
title = "Attenuation in the progression of cognitive deterioration in alzheimer's disease with rivastigmine: A dose-dependent effect",
abstract = "Objectives: Possible disease-modifying effects ofrivastigmine have been suggested by analyses using a variation of the randomized start design; however, the results were someichat confounded by differing attrition rales. We report on an alternative method investigating whether increasing doses reduce the rates of cognitive decline in patients who continue treatment. Methods: The effect of dose on the rate of cognitive decline seen on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASCog) u'as explored for patients in a long-term (130-iceek) extension of a 26-iceek placebo-controlled trial using two methods: a weighted least squares regression analysis using each individual's slope, and a weighted analysis of variance (ANOVA) comparing the slopes of patients categorized by dose (<6 mg/d or >6 mg/d). Results: The results from 408 patients included in the weighted least squares analysis estimated the rate of decline to attenuate by approximately 1 point/yfor every 3 mg/d increase (P<.0001). The average annual rate of decline for patients whose mean dose was >6 mg/d w-as 4.5 points (95{\%} Cl, 5.1-3.9), while for patients with a mean dose of>6 mg/d a decline of 8.2 points (95{\%} Cl, 9.1-7.3) was seen. Conclusion: These data further support earlier results suggesting that rivastigmine reduces the rate of progression of cognitive deterioration in Alzheimer's disease.",
author = "Martin Farlow and John Messina and Ravi Anand and Richard Hartman and Jeffrey Veach",
year = "2000",
language = "English",
volume = "5",
pages = "21--22",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "6",

}

TY - JOUR

T1 - Attenuation in the progression of cognitive deterioration in alzheimer's disease with rivastigmine

T2 - A dose-dependent effect

AU - Farlow, Martin

AU - Messina, John

AU - Anand, Ravi

AU - Hartman, Richard

AU - Veach, Jeffrey

PY - 2000

Y1 - 2000

N2 - Objectives: Possible disease-modifying effects ofrivastigmine have been suggested by analyses using a variation of the randomized start design; however, the results were someichat confounded by differing attrition rales. We report on an alternative method investigating whether increasing doses reduce the rates of cognitive decline in patients who continue treatment. Methods: The effect of dose on the rate of cognitive decline seen on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASCog) u'as explored for patients in a long-term (130-iceek) extension of a 26-iceek placebo-controlled trial using two methods: a weighted least squares regression analysis using each individual's slope, and a weighted analysis of variance (ANOVA) comparing the slopes of patients categorized by dose (<6 mg/d or >6 mg/d). Results: The results from 408 patients included in the weighted least squares analysis estimated the rate of decline to attenuate by approximately 1 point/yfor every 3 mg/d increase (P<.0001). The average annual rate of decline for patients whose mean dose was >6 mg/d w-as 4.5 points (95% Cl, 5.1-3.9), while for patients with a mean dose of>6 mg/d a decline of 8.2 points (95% Cl, 9.1-7.3) was seen. Conclusion: These data further support earlier results suggesting that rivastigmine reduces the rate of progression of cognitive deterioration in Alzheimer's disease.

AB - Objectives: Possible disease-modifying effects ofrivastigmine have been suggested by analyses using a variation of the randomized start design; however, the results were someichat confounded by differing attrition rales. We report on an alternative method investigating whether increasing doses reduce the rates of cognitive decline in patients who continue treatment. Methods: The effect of dose on the rate of cognitive decline seen on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASCog) u'as explored for patients in a long-term (130-iceek) extension of a 26-iceek placebo-controlled trial using two methods: a weighted least squares regression analysis using each individual's slope, and a weighted analysis of variance (ANOVA) comparing the slopes of patients categorized by dose (<6 mg/d or >6 mg/d). Results: The results from 408 patients included in the weighted least squares analysis estimated the rate of decline to attenuate by approximately 1 point/yfor every 3 mg/d increase (P<.0001). The average annual rate of decline for patients whose mean dose was >6 mg/d w-as 4.5 points (95% Cl, 5.1-3.9), while for patients with a mean dose of>6 mg/d a decline of 8.2 points (95% Cl, 9.1-7.3) was seen. Conclusion: These data further support earlier results suggesting that rivastigmine reduces the rate of progression of cognitive deterioration in Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=33746607732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746607732&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33746607732

VL - 5

SP - 21

EP - 22

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 6

ER -